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Radiation  pneumonitis  is an  important  cause  of  morbidity  after  concurrent  thoracic  chemoradiother-
apy  (CCRT).  However,  asymptomatic  changes  in lung  density  on  computed  tomography  (CT)-scans  occur
more  commonly,  and  correspond  to  regions  of  inﬂammatory  changes.  Characterization  of  dose-  and
time-related  changes  in  radiological  lung  density  (RLD)  may  facilitate  improved  radiation  planning,  and
allow  for  a  more  objective  measure  for assessing  damage.  We  studied  changes  in  RLD  following  CCRT
with  cisplatin–etoposide,  using  deformable  registration  to  co-register  follow-up  scans.  All  CT-scans  per-
formed  for  up  to 24 months  post-treatment  were  evaluated  in  25  patients  treated  with  CCRT  for  stage
III  non-small-cell  lung  cancer.  A total  of  104 scans  (median  of 3 per  patient)  were  co-registered  with
planning  scans  using  a deformable  registration  tool  (VelocityAI,  Atlanta,  USA).  Last  follow-up  scan  was  at
median  9.4  months  (range  3.4–22.6  months).  Seven  patients  developed  clinical  radiation  pneumonitis.
RLD  changes  (in  Hounsﬁeld  units)  were  measured  in  regions  receiving  3–66  Gy.  Linear mixed  models  were
used  to study  dose–density  changes  over  time.  No  signiﬁcant  changes  in  RLD  were  observed  in the  ﬁrst
3  months  post-treatment.  Increases  in  RLD  were  observed  at 3–6  months  (p < 0.0001)  and  6–12 months
(p  =  0.006),  but stabilized  at 1 year.  Increases  were  most  evident  in  regions  receiving  >30  Gy,  with  only
minor  density  changes  at lower  dose  levels.  Planning  target  volume  size  was  signiﬁcantly  associated  with
RLD  changes  (p =  0.03).  Limiting  lung  doses  to  ≤30 Gy during  CCRT  may  limit  sub-clinical  damage,  and  the
time-course  of RLD changes  may  allow  for early  quantiﬁcation  of  pulmonary  damage  when  evaluating
s.novel  treatment  strategie
. Introduction
Concurrent thoracic chemoradiotherapy (CCRT) is the stan-
ard of care in patients with stage III non-small-cell lung cancer
NSCLC) who have a good performance status [1]. Long-term sur-
ival remains disappointing, particularly in patients who  present
ith large volume disease who are also at risk for increased pul-
onary toxicity [2]. Some approaches for treatment intensiﬁcation
nclude the use of higher radiation doses and incorporation of
ovel systemic agents [3,4]. However, there is concern that more
ggressive schemes will increase treatment-related toxicity includ-
ng acute oesophagitis, neutropenia and anaemia, and radiation
neumonitis (RP) [1,5].
RP manifests as subacute toxicity as late as 1 year after treatment
ompletion [6]. The radiological appearance of radiation-induced
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lung disease is usually conﬁned to lung tissue within the radia-
tion port and manifests as ground-glass opacity, attenuation or as
consolidation in the acute phase, while in the late phase mainly
traction bronchiectasis, volume loss and scarring are observed [7].
The risk of RP can be predicted by use of parameters such as the
volume of lung tissue outside the planning target volume (PTV)
receiving a dose ≥20 Gy (V20), V5 and mean lung dose (MLD)  [8].
However, such parameters are imperfect predictors as fatal tox-
icity can also manifest in patients with low V20 [4]. Preclinical
studies have shown that radiological lung density (RLD) changes
correlate strongly with histopathological radiation damage and
physical endpoints [9]. Available data examining the relationship
between radiation dose and subsequently lung damage in humans
were derived from older studies which did not use high-resolution
computed tomography (CT)-scans and acceptable techniques for
co-registration of images, and which were not restricted to patients
Open access under the Elsevier OA license.with lung cancer [10–12]. Distinguishing between the phases of RP
and the subsequent formation of ﬁbrosis on CT-scan can be difﬁ-
cult, and both entities, therefore, are combined in the deﬁnition of
‘radiation-induced lung disease’ [13]. Objective and standardized
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iFig. 1. Two study cases demonstrating a central (A) and peripher
ethods for quantifying radiation-induced lung disease after CCRT
ould be useful in providing information on sub-clinical damage
hat occurs before the onset of overt clinical toxicity, and allow for
mprovements in radiotherapy planning and early detection of lung
njury.rimary tumour on planning scan and deformed follow-up scans.
We  previously evaluated quantitative changes in Hounsﬁeld
units (HU) in lung density on serial CT-scans performed after
stereotactic radiotherapy [14,15], and found that RLD changes
increased in a dose-dependent manner which correlated strongly
with physician-scored radiological pneumonitis. In contrast,
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Table 1
Patient and treatment characteristics.
Characteristic Result Range
Sex (n)
Male 16
Female 9
Age (y)
Median 65 48–78
Smoking (n)
Current 10
Former 12
Non 2
Unknown 1
Comorbidities (n)
COPD 4
Myocardial infarction 5
Diabetes 2
None 14
Clinical stage (n)
IIIA 14
IIIB 11
Primary location (n)
Right upper lobe 10
Middle lobe 1
Right lower lobe 4
Left upper lobe 3
Left lower lobe 1
Mediastinal 6
Planning parameters (median)
Total lung volume (cm3) 3643 2461–7034
PTV (cm3) 575 195–1258
V20 (%) 26.2 10.5–35.8
V5 (%) 50.9 23.4–83
Mean lung dose (Gy) 14.1 6.6–23.5
Total radiation dose (Gy)
46–58 10
60 9
66 6
COPD, chronic obstructive pulmonary disease; PTV, planning target volume; V , per-
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Fig. 2. Early (A) and late (B) changes in radiological lung density. The mean valuesn
entage volume of lung tissue outside the PTV receiving indicated threshold dose or
ore.
atients with stage III NSCLC constitute a more heterogeneous pop-
lation than patients with stage I disease, with a range of tumour
izes and lymph node involvement. Consequently, large radiation
elds are used in conjunction with chemotherapy, which increases
he risk of symptomatic radiation-induced lung disease. In the
resent study, we retrospectively evaluated RLD changes after CCRT
n patients with stage III NSCLC using the same technique.
. Materials and methods
.1. Patient selection and treatment details
Patients with stage III NSCLC who were treated using tho-
acic radiotherapy and concurrent full-dose cisplatin–etoposide
etween 2003 and 2008 [16] were assessed for eligibility in this
etrospective study. Eligible patients were required to have at least
ne CT-scan performed >3 months after completion of CCRT, and
oth chemotherapy and follow-up CT-scans had to be performed at
ur center. Treatment typically commenced with one course of cis-
latin 80 mg/m2 on day 1 with gemcitabine 1250 mg/m2 on days
 and 8, followed by 2–3 courses of cisplatin 80 mg/m2 (days 21
nd 42) and etoposide 100 mg/m2 (days 21–23 and 42–44). Once-
aily involved-ﬁeld thoracic radiotherapy commenced at day 22 (5
ays/week) in 2 Gy-fractions to a maximum of 66 Gy. During the
ime period of this study, doses of 50 Gy or higher were not rou-
inely administered at our center to patients who  presented with
ery bulky tumours and/or those with supraclavicular nodal metas-
ases, as the technique of intensity-modulated radiotherapy (IMRT)
as not (yet) available. A four-dimensional (4D) CT-scan was gen-and  95% conﬁdence intervals estimated from the linear mixed effects model are
presented. HU, Hounsﬁeld units.
erally used for treatment planning and all doses were recalculated
with the Analytical Anisotropic Algorithm (AAA) in Eclipse version
8.1 (Varian Medical Systems, Palo Alto, USA). Clinical RP (Grade ≥II)
was retrospectively assessed using the National Cancer Institute of
Common Toxicity Criteria (NCI-CTC) grading system v3.0. Patients
presenting with radiological signs of RP, and which was  also accom-
panied by clinically troublesome symptoms such as dyspnea, were
treated using steroids, typically prednisolone at a dose of 1 mg/kg
for 6 consecutive weeks followed by tapering the dose of steroids
to zero in the following 6 weeks.
2.2. Details of post-treatment CT-scans
Follow-up generally consisted of visits every 3–6 months until
2 years. All post-treatment diagnostic CT-scans were performed on
one of three different scanners. Machine settings were 120 kVp,
100 mAs, with spiral acquisition and a 0.5 s rotation time. Sev-
enty milliliter of contrast was administered for most patients
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Table  2
Lung dose–density changes post-treatment (CCRT).
Dose level (Gy) 0–3 months 3–6 months 6–12 months 12–24 months
Mean change (HU) 95% CI
3–30 −12 −34; 11 13 −7.3; 34 −4.1 −25; 17 3 −18; 24
30–40  6.3 −20; 33 44 19; 68 15 −9.9; 40 3.9 −20; 28
40–50  9.6 −17; 36 77 53; 100 56 31; 81 53 29; 76
50–60  7.3 −20; 34 120 94; 140 92 67; 120 91 67; 120
60–66  −10 −41; 20 160 130; 190 210 180; 240 230 190; 260
Patients (n) 18 21 15 11
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CRT, concurrent chemoradiotherapy; HU, Hounsﬁeld units; CI, conﬁdence interva
ith a delay of 25 s. Scans were acquired at inspiratory breath
old. All available scans after last radiotherapy fraction until 24
onths post-treatment were used for analysis if adequate regis-
ration could be achieved. Two scans were excluded as they could
ot be registered accurately with the planning scan using the
eformable registration technique, and one scan was excluded as
t was repeated 3 days after a previous scan. In total, 104 follow-
p scans were analyzed, with a median of 3 per patient (range
–10 scans). Median radiological follow-up for all included patients
ithin the study period of 24 months post-treatment was  9.4
onths (range 3.4–22.6 months).
.3. Image registration and lung density measurements
The method of image registration/deformation has been
escribed previously [14,15]. Brieﬂy, the post-treatment scans
ere co-registered with planning scans using a B-spline
eformable registration algorithm (VelocityAI, Atlanta, USA). Con-
ours of selected isodose levels (3 Gy, 5 Gy, 15 Gy, 30 Gy, 40 Gy,
0 Gy, 60 Gy) were exported from the planning system along with
he contours of the lung, internal target volume (ITV), and the
verage-intensity CT dataset. The isodose lines were chosen so as to
rovide a wide range of doses and large enough volumes between
sodose lines to allow for meaningful lung density measurements.
ung receiving <3 Gy was considered un-irradiated and as such was
sed to correct for baseline differences between scanners. After
eformation of the follow-up scans to match the end-inspiratory
hase of the planning scan, isodoses from the planning scan were
hen overlaid on the deformed follow-up scan, and checked for
nconsistencies. The area within the target was not analyzed, to
void confounding by changes in tumour density. Subsequently,
hanges in HU density were measured. Fig. 1 demonstrates a cen-
ral (A) and peripheral (B) primary tumour, showing the planning
can and deformed follow-up scans.
.4. Statistical analysis
Linear mixed models were constructed to assess the association
etween RLD changes and radiation dose over time. Patient and
T-scan were implemented as the random grouping variables, thus
djusting for any within-patient correlations and the inﬂuence of
ifferent scanners. Radiation dose (3–5, 5–15, 15–30, 30–40, 40–50,
0–60 and 60–66 Gy), time post-treatment (0–3, 3–6, 6–12 and
2–24 months) and their interaction were taken as discrete ﬁxed
ffects. Overall F tests were used to assess signiﬁcance of the inter-
ction term, and pairwise tests were performed to determine which
egions differed between dose levels and time intervals. The asso-
iation between RLD changes and patient characteristics; smoking
current vs. former/non/unknown), age (≤65 vs. >65 years), PTV
≤575 vs. >575 cm3), V20 (≤30 vs. >30%), V5 (≤50 vs. >50%), MLD
≤15 vs. >15 Gy), and clinical symptoms of RP (present vs. absent)
as also assessed by including these variates as dichotomous ﬁxed26 33
omputed tomography.
effects. In all analyses the restricted maximum likelihood estimates
are reported, tests were two-sided when appropriate, and the sig-
niﬁcance level was  taken at the 0.05 threshold. All analyses were
performed in R (v2.10.1).
3. Results
Of 89 stage III NSCLC patients described in our deﬁnite CCRT
cohort [16], 50 were treated with both chemo- and radiotherapy
at the VU University Medical Center. Of these, 25 patients were
excluded for the following reasons: no available follow-up scans
(n = 7); disease progression within 3 months after last radiother-
apy (n = 7); difﬁculty with registration due to atelectasis (n = 4) or
ﬁstula/empyema (n = 2); previous pneumonectomy (n = 2); death
during treatment (n = 2), and drop-out of CCRT after 40 Gy (n = 1).
Baseline and treatment characteristics of the remaining 25 patients
who were eligible are summarized in Table 1. Eight included
patients were treated for a recurrent NSCLC in the ipsilateral lung
(n = 2) or mediastinum (n = 6). Of these, 7 had undergone previous
resection, while 1 had regional progression after stereotactic radio-
therapy. After CCRT, 7 patients developed clinical RP; grade II (n = 5)
or grade III (n = 2).
3.1. Temporal changes in CT lung density (HU)
Fig. 2 shows the relationship between RLD changes and dose
levels during 4 time intervals after CCRT, and these were classiﬁed
as early (0–6 months) vs. late (6–24 months). Compared to plan-
ning scan, RLD changes within the ﬁrst 3 months post-treatment
were not different for any dose level (p = 0.13). RLD increases after
3 months and stabilized at 1 year: the differences in RLD changes
between the 0 and 3 vs. 3 and 6 month periods were highly signiﬁ-
cant (p < 0.0001), as were differences between the 3 and 6 vs. 6 and
12 month period (p = 0.006), but not between the 6 and 12 vs. 12 and
24 month periods (p = 0.67). RLD change was  not evident in regions
receiving <30 Gy (p = 0.23). A slight increase in RLD was  evident in
regions receiving 30–40 Gy (p = 0.02), with more pronounced RLD
evident with increasing dose in higher dose areas (30–40 Gy  vs.
40–50 Gy, p = 0.003; 40–50 Gy vs. 50–60 Gy, p = 0.003; 50–60 Gy vs.
60–66 Gy, p < 0.0001).
Table 2 summarizes the mean RLD changes in HU and 95% con-
ﬁdence interval (CI) for 5 dose levels during the different time
intervals. Examining other variables by comparing patient groups,
only large PTV (above the median of 575 cm3) was associated with
an increase in RLD (mean 64.9 HU; 95% CI: 11.0–118.7; p = 0.03).
No association was found for: smoking (p = 0.18), age (p = 0.56), V20
(p = 0.58), V5 (p = 0.92), MLD  (p = 0.67), clinical RP (p = 0.57).4. Discussion
To our knowledge, this is the ﬁrst study investigating radiation-
induced lung disease by measuring RLD changes on serial CT-scans
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n patients receiving modern, standard of care CCRT with a
latin-based doublet and 3D volumetric radiation treatment with
nhomogeneity corrections. We  applied a novel method that uses
eformable registration, which signiﬁcantly improves accuracy
ver rigid registration techniques [14]. Signiﬁcant increases in RLD
re observed as early as 3 months after the last fraction of radiother-
py, and at a dose threshold of 30 Gy. Furthermore, RLD increases
ecome more apparent in higher dose regions, and are more pro-
ounced in patients with larger target volumes.
This approach of measuring RLD changes on serial CT-scans after
CRT appears to be promising in several ways. Objective quantiﬁ-
ation of RLD changes may  contribute to a better understanding
f the development of all radiation-induced lung disease, and the
dentiﬁcation of a threshold dose of 30 Gy when using full-dose
isplatin–etoposide suggests that it could be used as a constraint
ose for treatment planning. Modern delivery technologies such as
espiratory gated and intensity modulated radiotherapy can allow
or appropriate redistribution of lung doses using such constraints
17]. Measurement of RLD in protocols could potentially be used to
creen for unexpected increases in early radiological changes (espe-
ially in low-dose regions) when investigating new chemotherapy
gents or higher radiation doses or fractionation schedules. An
xample of a change in chemotherapy that may  have exacerbated
P was observed in the randomized HOG-LUN 01–24 trial of CCRT
sing cisplatin–etoposide, followed by treatment with or with-
ut consolidation docetaxel. Clinical RP was reported in 14.6% of
atients receiving docetaxel, but only 3.6% in the other arm [18]. In
 comparison between conventional radiotherapy and continuous
yperfractionated, accelerated radiotherapy (CHART), respectively
9% and 10% of study patients had clinically relevant RP within ﬁrst
 months post-treatment, however at longer follow-up analysis (2
ears) there was a trend for more ‘troublesome’ clinical RP in the
HART study arm [19].
The use of CT-scans for quantitative measurement of radiation-
nduced lung disease was reported as early as 1988 [10]. A
ubsequent prospective study in 119 patients with breast can-
er undergoing postoperative radiotherapy studied mean lung
ensity changes on CT-scans [11]. A study in a heterogeneous
roup of patients who received thoracic radiotherapy or CCRT
mostly for lung cancer) found RLD changes to correlate with
ncreasing dose, and which increased during the ﬁrst 6 months
ost-treatment before levelling off [12]. In patients treated with
tereotactic radiotherapy, however, a threshold dose of 6 Gy was
ound to be associated with increased density of normal lung tis-
ue, with changes increasing after 6 months and plateauing at 40 Gy
15]. Our present study builds upon this previously published data,
roviding further understanding of the spatial and temporal distri-
ution of these changes using a more accurate dose calculation and
mage registration technique, in a group of patients treated with a
odern CCRT regimen.
The ﬁndings of this study must be considered in the context
f its limitations. The study is retrospective in nature, and patient
nclusion was based on the availability of CT-scans. This may  have
esulted in a highly selected patient cohort, which could in turn
imit the generalizability of the conclusions and introduce con-
ounders. Furthermore, the median radiological follow-up of 9.4
onths in the present cohort is less than median survival observed
n patients treated using CCRT outside clinical trials [16]. The fact
hat correlations were not observed between RLD changes and
atient factors, dosimetric parameters and clinical RP, is likely
ue to the limited power with this sample size and the lack of a
onger follow-up. Only seven patients in this cohort experienced
linically relevant RP, which is a subjective diagnosis that can be
ifﬁcult in this patient population. In addition, early medical inter-
ention of RP with steroids improves both clinical and radiological
ppearance of the patient, which could inﬂuence lung density
[ancer 74 (2011) 451– 456 455
measurements and correlation with clinical endpoints. However,
pre-clinical data indicates a good correlation between CT density
changes and histopathological changes in lung tissue [9].
In conclusion, this study on serial CT-scans after full-dose CCRT
in stage III NSCLC patients demonstrates a threshold dose of 30 Gy
for increased lung dose–density changes, with RLD increasing 3
months after treatment and plateauing by 1 year. The relation-
ship between radiation-induced lung disease and development of
clinical toxicity is unclear, and further research is needed to cor-
relate these quantitatively-measured RLD changes with clinical
endpoints.
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